|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
10.80 Billion
|
|
CAGR (2025-2030)
|
4.73%
|
|
Fastest Growing Segment
|
Sex Hormones
|
|
Largest Market
|
Midwest
|
|
Market Size (2030)
|
USD 14.09 Billion
|
Market Overview
United States Hormone Therapy (Retail
Side) Market was valued at USD 10.80 Billion in 2024 and is expected to reach USD
14.09 Billion by 2030 with a CAGR of 4.73%. Hormone therapy involves the
administration of hormones to treat a wide range of conditions, including
menopause symptoms, thyroid disorders, testosterone deficiency, growth hormone
deficiencies, and certain cancers. In recent years, the retail distribution of
hormone therapies has expanded significantly, fueled by the increasing trend
toward patient-centered care and home-based treatment. Many hormone therapies
are now available in user-friendly formats such as oral tablets, transdermal
patches, topical creams, and injectable pens, allowing for ease of use and
greater adherence outside of clinical settings.
However, the retail hormone therapy
market also faces challenges. These include ongoing debates over the long-term
safety of certain hormone treatments particularly in postmenopausal women as
well as concerns around misuse, overprescription, and the availability of
unregulated or compounded hormone products. Moreover, insurance coverage for
some therapies, especially bioidentical hormone treatments, can be
inconsistent, impacting patient access and affordability.
Key Market Drivers
Growth
in Healthcare Industry
In 2023, U.S. healthcare expenditures increased by
7.5%, reaching USD 4.9 trillion equating to approximately USD 14,570 per
person. This spending represented 17.6% of the nation's Gross Domestic Product
(GDP). The expanding healthcare industry in the United States is a pivotal
factor propelling the growth of the hormone therapy market on the retail side.
Advances in medical research, increased healthcare spending, and greater access
to healthcare services have collectively contributed to a rising demand for
hormone therapy products.
The population of Americans aged 65 and older is
projected to grow from 58 million in 2022 to 82 million by 2050, representing a
47% increase. Additionally, this age group’s proportion of the total U.S.
population is expected to rise from 17% to 23%. With an aging
population and a growing prevalence of hormone-related conditions such as
menopause, osteoporosis, and hypogonadism, healthcare providers are
increasingly recommending hormone replacement therapies (HRT) to improve
patient quality of life. This trend is further amplified by the heightened
awareness and acceptance of hormone therapies among patients, driven by
education and outreach efforts.
Surge
in Technological Advancements
The United States hormone therapy market on the retail
side is experiencing strong momentum, largely driven by a surge in
technological advancements across drug formulation, delivery systems, and
personalized medicine. Innovations such as transdermal patches,
sustained-release injectables, and bioidentical hormone therapies have
significantly improved the safety, efficacy, and convenience of treatment
options. These advancements are enhancing patient adherence and expanding
access through retail pharmacies.
Additionally, progress in diagnostic tools and hormone
level monitoring technologies is enabling more precise and individualized
treatment plans, further supporting the shift toward consumer-driven,
outpatient hormone therapy. For instance, the VIDAS Fertility Panel offers
essential diagnostic tools for assessing eight distinct reproductive hormone
disorders. BioMérieux provides a robust, reliable, and clinically validated
solution that enables convenient on-site testing at fertility centers. Digital
health platforms and telemedicine integration are also playing a critical role,
allowing for remote prescription management and increasing retail distribution.
As patients and providers seek more effective, accessible, and tailored
solutions, technological innovation remains a key growth driver in the retail
hormone therapy space.
Download Free Sample Report
Key Market Challenges
Disruptions
in Supply Chain
Disruptions in the supply chain pose a
significant challenge to the United States Hormone Therapy Market on the retail
side. The production and distribution of hormone therapies depend on a complex
network of raw material suppliers, manufacturers, distributors, and retail
pharmacies. Any interruption at any point in this chain whether due to
manufacturing delays, shortages of active pharmaceutical ingredients (APIs),
transportation bottlenecks, or regulatory hurdles can lead to product scarcity
and delayed availability at the retail level.
Such supply chain disruptions not only
affect the timely delivery of hormone therapies but can also impact pricing and
inventory management. Pharmacies may face difficulties in maintaining
consistent stock levels, which in turn can undermine patient adherence and
trust. Patients requiring continuous hormone therapy, such as those undergoing
hormone replacement therapy or managing endocrine disorders, are particularly
vulnerable to interruptions, as inconsistent access can lead to suboptimal
treatment outcomes and increased healthcare costs.
Key Market Trends
Integration
of Telehealth and Online Platforms
The integration of telehealth services
and online platforms is emerging as a significant trend in the United States
hormone therapy market, particularly on the retail side. A national study
analyzing private insurance claims data from 36 million working-age individuals
revealed a 766% increase in telemedicine encounters during the first three
months of the pandemic. This trend aligns with findings from Doximity, an
online medical networking platform representing approximately 1.8 million
physicians about 80% of the U.S. physician workforce which estimated that
nearly 20% of all healthcare visits in the U.S. in 2020 were conducted via
telemedicine based on private claims data. This shift is driven by evolving
consumer preferences for convenience, accessibility, and personalized
healthcare solutions.
Telehealth enables patients to consult
healthcare professionals remotely, reducing barriers such as geographic
distance, time constraints, and mobility issues. This is especially beneficial
for hormone therapy patients, who often require ongoing consultations and
monitoring. The ability to receive expert guidance and prescriptions through
virtual channels has made hormone therapy more accessible to a broader
demographic, including those in rural or underserved areas.
Segmental Insights
Product
Insights
Based on Product, Sex Hormones have
emerged as the fastest growing segment in the United States Hormone Therapy
(Retail Side) Market in 2024. This is due to rising awareness of
hormone-related health issues and increasing demand for treatments addressing
menopause, testosterone deficiency, and reproductive health. Innovations in
formulation and delivery methods such as bioidentical hormones, transdermal
patches, and gels have improved patient convenience, safety, and efficacy,
driving greater adoption.
Indication
Insights
Based on Indication, Menopause &
Andropause Management have emerged as the fastest growing segment in the United
States Hormone Therapy (Retail Side) Market during the forecast period. This is
due to increasing awareness and demand for effective treatments that address
the symptoms associated with hormonal decline in aging populations. As more
individuals seek to improve their quality of life and manage symptoms such as
hot flashes, mood swings, fatigue, and decreased libido, hormone therapies
specifically targeting menopause and andropause have gained significant
traction.
Download Free Sample Report
Regional Insights
Based on Region, Midwest have emerged as
the dominating region in the United States Hormone Therapy (Retail Side) Market
in 2024. This is due to several strategic and operational advantages. The
region benefits from a well-established pharmaceutical manufacturing
infrastructure, which supports large-scale production and distribution of
hormone therapies. Its central geographic location facilitates efficient
logistics, enabling faster and cost-effective delivery to both urban and rural
markets across the country.
Recent Development
- In February 2025, The HRT Club
officially launched its direct-to-consumer (DTC) hormone replacement therapy
platform, targeting disruption of the USD 7.4 billion U.S. hormonal care
market. By removing insurance barriers and reducing costs by up to 90% for
members, the company aims to significantly increase accessibility and
affordability. Offering a USD 99 annual membership, supported by partnerships
with drug manufacturers and a technology-driven platform, The HRT Club plans to
expand its member base to 50,000. Future initiatives include introducing new
hormonal therapies such as glucagon-like peptide-1 (GLP-1) medications and
enhancing telehealth capabilities with features like an integrated pharmacy
system for prescription management and a streamlined interface for virtual
consultations.
- In January 2025, AstraZeneca and Daiichi
Sankyo’s Enhertu (trastuzumab deruxtecan) received FDA approval in the U.S. for
the treatment of adult patients with unresectable or metastatic hormone
receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC
0 with membrane staining) breast cancer, as identified by an FDA-approved
diagnostic test. The approval applies to patients whose disease has progressed
following one or more endocrine therapies in the metastatic setting. This FDA
approval followed Priority Review and Breakthrough Therapy Designation, based
on data from the Phase III DESTINY-Breast06 trial, which was presented at the
2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
- In January 2024, Merck, operating as MSD
outside the United States and Canada, announced the initiation of pivotal Phase
3 clinical trials for four investigational candidates from its broad and
diverse oncology pipeline, focused on hematologic malignancies and solid
tumors. These Phase 3 trial launches represent a critical advancement in
Merck’s ongoing efforts to develop innovative treatment options aimed at
improving outcomes for patients with both solid tumors and hematologic cancers.
This milestone underscores the company’s commitment to addressing significant
unmet medical needs across multiple cancer types.
- In May 2025, Astellas Pharma Inc. and
Pfizer Inc. announced long-term follow-up results from the open-label extension
of the Phase 3 ARCHES study, demonstrating a five-year overall survival (OS)
benefit. The data showed a 30% reduction in the risk of death among men with
metastatic hormone-sensitive prostate cancer (mHSPC) treated with XTANDI
(enzalutamide), an androgen receptor pathway inhibitor (ARPI), combined with
androgen deprivation therapy (ADT), compared to placebo plus ADT. These
findings will be presented in an oral session at the upcoming American Society
of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Key Market Players
- CVS
Health
- Walgreens
Boots Alliance, Inc.
- Walmart
Pharmacy
- Rite
Aid Corp
- The
Kroger Co.
- Albertsons
- Costco
Wholesale Corporation
- Mark
Cuban Cost Plus Drug Company, PBC
- Blink
Health Administration LLC, Inc.
- GoodRx,
Inc.
|
By Product
|
By Indication
|
By Region
|
- Sex Hormones
- Thyroid Hormones
- Growth Hormones
- Adrenal Hormones
- Others
|
- Menopause & Andropause Management
- Hypothyroidism
- Hypogonadism
- Growth Hormone Deficiency
- Fertility Treatment
- Others
|
- Northeast
- Midwest
- South
- West
|
Report Scope
In this report, the United States Hormone Therapy
(Retail Side) Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- United States Hormone
Therapy (Retail Side) Market, By Product:
o Sex Hormones
o Thyroid Hormones
o Growth Hormones
o Adrenal Hormones
o Others
- United States Hormone
Therapy (Retail Side) Market, By Indication:
o Menopause & Andropause Management
o Hypothyroidism
o Hypogonadism
o Growth Hormone Deficiency
o Fertility Treatment
o Others
- United States Hormone
Therapy (Retail Side) Market, By Region:
o Northeast
o Midwest
o South
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the United States Hormone Therapy (Retail Side) Market.
Available Customizations:
United States Hormone Therapy (Retail Side) Market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
United States Hormone
Therapy (Retail Side) Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]